{
    "_id": "2dd928b00e8644e488ffe670e9aa13e8",
    "_pm_abstract": [
        {
            "Label": "BACKGROUND",
            "text": "Antitumor activity of ipilimumab or BRAF ± MEK inhibitors (BRAFi ± MEKi) following pembrolizumab administration in melanoma is poorly characterized."
        },
        {
            "Label": "PATIENTS AND METHODS",
            "text": "In the phase III KEYNOTE-006 study, patients with unresectable stage III/IV melanoma received pembrolizumab (10 mg/kg) once every 2 or 3 weeks (Q3W) or ipilimumab (3 mg/kg) Q3W. The current post hoc analysis evaluates outcomes with ipilimumab or BRAFi ± MEKi as first subsequent systemic therapy after pembrolizumab administration and includes patients who completed or discontinued pembrolizumab after one or more dose. Pembrolizumab arms were pooled."
        },
        {
            "Label": "RESULTS",
            "text": "At data cut-off (4 December 2017), median follow-up was 46.9 months. Of 555 pembrolizumab-treated patients, first subsequent therapy was ipilimumab for 103 (18.6%) and BRAFi ± MEKi for 59 (10.6%) [33 received BRAFi + MEKi, 26 BRAFi alone; 37 (62.7%) were BRAFi ± MEKi naïve]. In the subsequent ipilimumab group, ORR with previous pembrolizumab was 17.5% [1 complete response (CR); 17 partial response (PR)]; 79.6% had discontinued pembrolizumab due to progressive disease (PD); median overall survival (OS) was 21.5 months. ORR with subsequent ipilimumab was 15.5%; 11/16 responses (8 CRs; 3 PRs) were ongoing. ORR with subsequent ipilimumab was 9.7% for patients with PD as best response to pembrolizumab. Median OS from ipilimumab initiation was 9.8 months. In the subsequent BRAFi ± MEKi group, ORR with previous pembrolizumab was 13.5% (8 PR); 76.3% had discontinued pembrolizumab due to PD; median OS was 17.9 months. ORR with subsequent BRAFi ± MEKi was 30.5%, 7/18 responses (4 CR, 3 PR) were ongoing. Median OS from BRAFi ± MEKi initiation was 12.9 months. ORR for BRAFi ± MEKi-naïve patients who received subsequent BRAFi ± MEKi was 43.2%; 6/16 were ongoing (3 CR, 3 PR)."
        },
        {
            "Label": "CONCLUSIONS",
            "text": "Ipilimumab and BRAFi ± MEKi have antitumor activity as first subsequent therapy after pembrolizumab in patients with advanced melanoma."
        }
    ],
    "_pm_abstract_raw": "Antitumor activity of ipilimumab or BRAF ± MEK inhibitors (BRAFi ± MEKi) following pembrolizumab administration in melanoma is poorly characterized. In the phase III KEYNOTE-006 study, patients with unresectable stage III/IV melanoma received pembrolizumab (10 mg/kg) once every 2 or 3 weeks (Q3W) or ipilimumab (3 mg/kg) Q3W. The current post hoc analysis evaluates outcomes with ipilimumab or BRAFi ± MEKi as first subsequent systemic therapy after pembrolizumab administration and includes patients who completed or discontinued pembrolizumab after one or more dose. Pembrolizumab arms were pooled. At data cut-off (4 December 2017), median follow-up was 46.9 months. Of 555 pembrolizumab-treated patients, first subsequent therapy was ipilimumab for 103 (18.6%) and BRAFi ± MEKi for 59 (10.6%) [33 received BRAFi + MEKi, 26 BRAFi alone; 37 (62.7%) were BRAFi ± MEKi naïve]. In the subsequent ipilimumab group, ORR with previous pembrolizumab was 17.5% [1 complete response (CR); 17 partial response (PR)]; 79.6% had discontinued pembrolizumab due to progressive disease (PD); median overall survival (OS) was 21.5 months. ORR with subsequent ipilimumab was 15.5%; 11/16 responses (8 CRs; 3 PRs) were ongoing. ORR with subsequent ipilimumab was 9.7% for patients with PD as best response to pembrolizumab. Median OS from ipilimumab initiation was 9.8 months. In the subsequent BRAFi ± MEKi group, ORR with previous pembrolizumab was 13.5% (8 PR); 76.3% had discontinued pembrolizumab due to PD; median OS was 17.9 months. ORR with subsequent BRAFi ± MEKi was 30.5%, 7/18 responses (4 CR, 3 PR) were ongoing. Median OS from BRAFi ± MEKi initiation was 12.9 months. ORR for BRAFi ± MEKi-naïve patients who received subsequent BRAFi ± MEKi was 43.2%; 6/16 were ongoing (3 CR, 3 PR). Ipilimumab and BRAFi ± MEKi have antitumor activity as first subsequent therapy after pembrolizumab in patients with advanced melanoma.",
    "_pm_id": "34710571",
    "_pm_title": "Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006.",
    "_umls_result": [
        {
            "_semantic_type": "Patient or Disabled Group",
            "all_matches": [
                {
                    "_term": "patients",
                    "concepts": [
                        "('C0030705', 'patients', 'Patient or Disabled Group', 'SY', 'CHV')",
                        "('C0030705', 'Patients', 'Patient or Disabled Group', 'PT', 'PSY')",
                        "('C0030705', 'Patients', 'Patient or Disabled Group', 'PT', 'LCH_NW')",
                        "('C0030705', 'Patients', 'Patient or Disabled Group', 'PN', 'MTH')",
                        "('C0030705', 'Patients', 'Patient or Disabled Group', 'MH', 'MSH')",
                        "('C0030705', 'Patients', 'Patient or Disabled Group', 'SY', 'NCI')"
                    ]
                }
            ]
        },
        {
            "_semantic_type": "Neoplastic Process",
            "all_matches": [
                {
                    "_term": "advanced melanoma",
                    "concepts": [
                        "('C4727838', 'Advanced Melanoma', 'Neoplastic Process', 'PT', 'NCI')"
                    ]
                },
                {
                    "_term": "melanoma",
                    "concepts": [
                        "('C0025202', 'melanoma', 'Neoplastic Process', 'PSC', 'PDQ')",
                        "('C0025202', 'Melanoma', 'Neoplastic Process', 'SY', 'NCI_caDSR')",
                        "('C0025202', 'Melanoma', 'Neoplastic Process', 'PT', 'NCI_CTEP-SDC')",
                        "('C0025202', 'melanoma', 'Neoplastic Process', 'PT', 'CSP')",
                        "('C0025202', 'Melanoma', 'Neoplastic Process', 'DN', 'NCI_CTRP')",
                        "('C1302746', 'Melanoma', 'Neoplastic Process', 'SY', 'SNOMEDCT_VET')",
                        "('C0025202', 'Melanoma', 'Neoplastic Process', 'LLT', 'MDR')",
                        "('C0025202', 'Melanoma', 'Neoplastic Process', 'PT', 'NCI')",
                        "('C0025202', 'Melanoma', 'Neoplastic Process', 'MH', 'MSH')",
                        "('C0025202', 'melanoma', 'Neoplastic Process', 'PTN', 'ICPC2P')",
                        "('C0025202', 'Melanoma', 'Neoplastic Process', 'PT', 'MEDLINEPLUS')",
                        "('C0025202', 'Melanoma', 'Neoplastic Process', 'PT', 'NCI_NICHD')",
                        "('C0025202', 'Melanoma', 'Neoplastic Process', 'PT', 'NCI_CELLOSAURUS')",
                        "('C0025202', 'Melanoma', 'Neoplastic Process', 'PT', 'ICPC2P')",
                        "('C0025202', 'Melanoma', 'Neoplastic Process', 'PT', 'NCI_CTRP')",
                        "('C0025202', 'melanoma', 'Neoplastic Process', 'PN', 'MTH')",
                        "('C0025202', 'Melanoma', 'Neoplastic Process', 'PT', 'NCI_GDC')",
                        "('C0025202', 'Melanoma', 'Neoplastic Process', 'PTCS', 'OMIM')",
                        "('C0025202', 'Melanoma', 'Neoplastic Process', 'PT', 'HPO')",
                        "('C0025202', 'Melanoma', 'Neoplastic Process', 'SY', 'SNOMEDCT_US')",
                        "('C0025202', 'melanoma', 'Neoplastic Process', 'PT', 'CHV')",
                        "('C0025202', 'melanoma', 'Neoplastic Process', 'PT', 'ICPC2ICD10ENG')",
                        "('C0025202', 'Melanoma', 'Neoplastic Process', 'LA', 'LNC')",
                        "('C0025202', 'Melanoma', 'Neoplastic Process', 'PT', 'LCH_NW')",
                        "('C0025202', 'melanoma', 'Neoplastic Process', 'PT', 'NCI_NCI-GLOSS')"
                    ]
                },
                {
                    "_term": "stage iii",
                    "concepts": [
                        "('C4551545', 'Stage III', 'Neoplastic Process', 'PT', 'NCI_PCDC')",
                        "('C3829185', 'Stage III', 'Neoplastic Process', 'PT', 'NCI_GDC')"
                    ]
                },
                {
                    "_term": "arms",
                    "concepts": [
                        "('C0206655', 'ARMS', 'Neoplastic Process', 'PT', 'NCI_NCI-GLOSS')"
                    ]
                },
                {
                    "_term": "progressive disease",
                    "concepts": [
                        "('C0677932', 'progressive disease', 'Neoplastic Process', 'PT', 'NCI_NCI-GLOSS')"
                    ]
                }
            ]
        },
        {
            "_semantic_type": "Finding",
            "all_matches": [
                {
                    "_term": "poorly",
                    "concepts": [
                        "('C4761380', 'Poorly', 'Finding', 'SY', 'NCI_caDSR')"
                    ]
                },
                {
                    "_term": "discontinued",
                    "concepts": [
                        "('C1444662', 'DISCONTINUED', 'Finding', 'PT', 'NCI_CDISC')",
                        "('C1444662', 'Discontinued', 'Finding', 'PT', 'SNOMEDCT_US')",
                        "('C1444662', 'Discontinued', 'Finding', 'AD', 'NCI')",
                        "('C1444662', 'Discontinued', 'Finding', 'PN', 'MTH')"
                    ]
                },
                {
                    "_term": "follow-up",
                    "concepts": [
                        "('C0589120', 'Follow-up', 'Finding', 'SY', 'SNOMEDCT_US')",
                        "('C0589120', 'Follow-up', 'Finding', 'LA', 'LNC')",
                        "('C0589120', 'follow-up', 'Finding', 'SY', 'CHV')"
                    ]
                },
                {
                    "_term": "complete response",
                    "concepts": [
                        "('C0677874', 'Complete Response', 'Finding', 'PT', 'NCI_GDC')",
                        "('C0677874', 'Complete Response', 'Finding', 'SY', 'NCI_CDISC')",
                        "('C5203033', 'Complete Response', 'Finding', 'SY', 'NCI_caDSR')",
                        "('C5203022', 'Complete Response', 'Finding', 'SY', 'NCI_caDSR')",
                        "('C0677874', 'complete response', 'Finding', 'PT', 'CHV')",
                        "('C0677874', 'Complete Response', 'Finding', 'PT', 'NCI_ICDC')",
                        "('C0677874', 'complete response', 'Finding', 'PT', 'NCI_NCI-GLOSS')",
                        "('C5401353', 'Complete Response', 'Finding', 'SY', 'NCI_caDSR')",
                        "('C0677874', 'Complete Response', 'Finding', 'SY', 'NCI_caDSR')",
                        "('C5203025', 'Complete Response', 'Finding', 'SY', 'NCI')",
                        "('C0677874', 'Complete response', 'Finding', 'LA', 'LNC')",
                        "('C0677874', 'Complete Response', 'Finding', 'PT', 'NCI_PCDC')",
                        "('C5203023', 'Complete Response', 'Finding', 'SY', 'NCI_caDSR')",
                        "('C0677874', 'Complete response', 'Finding', 'PT', 'NCI_CTDC')",
                        "('C5203024', 'Complete Response', 'Finding', 'SY', 'NCI_caDSR')",
                        "('C5203035', 'Complete Response', 'Finding', 'SY', 'NCI_caDSR')",
                        "('C4724446', 'Complete Response', 'Finding', 'SY', 'NCI')",
                        "('C5203034', 'Complete Response', 'Finding', 'SY', 'NCI')"
                    ]
                },
                {
                    "_term": "partial response",
                    "concepts": [
                        "('C1521726', 'partial response', 'Finding', 'PN', 'MTH')",
                        "('C1521726', 'Partial Response', 'Finding', 'SY', 'NCI_caDSR')",
                        "('C5202622', 'Partial Response', 'Finding', 'SY', 'NCI_caDSR')",
                        "('C1521726', 'Partial Response', 'Finding', 'SY', 'NCI_CDISC')",
                        "('C1521726', 'Partial Response', 'Finding', 'PT', 'NCI_PCDC')",
                        "('C5202621', 'Partial Response', 'Finding', 'SY', 'NCI_caDSR')",
                        "('C5401418', 'Partial Response', 'Finding', 'SY', 'NCI_caDSR')",
                        "('C1521726', 'partial response', 'Finding', 'PT', 'NCI_NCI-GLOSS')",
                        "('C5202892', 'Partial Response', 'Finding', 'SY', 'NCI')",
                        "('C1521726', 'Partial response', 'Finding', 'LA', 'LNC')",
                        "('C5202623', 'Partial Response', 'Finding', 'SY', 'NCI_caDSR')",
                        "('C1521726', 'Partial Response', 'Finding', 'PT', 'NCI_GDC')",
                        "('C1521726', 'Partial Response', 'Finding', 'SY', 'NCI')",
                        "('C1521726', 'Partial Response', 'Finding', 'PT', 'NCI_ICDC')",
                        "('C4723835', 'Partial Response', 'Finding', 'SY', 'NCI')",
                        "('C5202620', 'Partial Response', 'Finding', 'SY', 'NCI_caDSR')",
                        "('C5202624', 'Partial Response', 'Finding', 'SY', 'NCI')",
                        "('C1521726', 'Partial response', 'Finding', 'PT', 'NCI_CTDC')",
                        "('C5202891', 'Partial Response', 'Finding', 'SY', 'NCI_caDSR')"
                    ]
                },
                {
                    "_term": "progressive disease",
                    "concepts": [
                        "('C5202925', 'Progressive Disease', 'Finding', 'SY', 'NCI_caDSR')",
                        "('C5202920', 'Progressive Disease', 'Finding', 'SY', 'NCI_caDSR')",
                        "('C5202924', 'Progressive Disease', 'Finding', 'SY', 'NCI')",
                        "('C5202921', 'Progressive Disease', 'Finding', 'SY', 'NCI')",
                        "('C5202991', 'Progressive Disease', 'Finding', 'SY', 'NCI')",
                        "('C4723839', 'Progressive Disease', 'Finding', 'SY', 'NCI')",
                        "('C5202923', 'Progressive Disease', 'Finding', 'SY', 'NCI_caDSR')",
                        "('C5202926', 'Progressive Disease', 'Finding', 'SY', 'NCI_caDSR')"
                    ]
                },
                {
                    "_term": "best response",
                    "concepts": [
                        "('C2986560', 'Best Response', 'Finding', 'SY', 'NCI_CDISC')",
                        "('C2986560', 'best response', 'Finding', 'SY', 'NCI_ICDC')"
                    ]
                }
            ]
        },
        {
            "_semantic_type": "Clinical Attribute",
            "all_matches": [
                {
                    "_term": "unresectable",
                    "concepts": [
                        "('C1519810', 'Unresectable', 'Clinical Attribute', 'SY', 'NCI_NICHD')",
                        "('C1519810', 'unresectable', 'Clinical Attribute', 'PT', 'NCI_NCI-GLOSS')",
                        "('C1519810', 'Unresectable', 'Clinical Attribute', 'PT', 'NCI')",
                        "('C1519810', 'unresectable', 'Clinical Attribute', 'PT', 'CHV')"
                    ]
                },
                {
                    "_term": "dose",
                    "concepts": [
                        "('C1114758', 'Dose', 'Clinical Attribute', '#OSN', 'LNC')"
                    ]
                }
            ]
        },
        {
            "_semantic_type": "Therapeutic or Preventive Procedure",
            "all_matches": [
                {
                    "_term": "systemic",
                    "concepts": [
                        "('C5400982', 'Systemic', 'Therapeutic or Preventive Procedure', 'PT', 'NCI_PCDC')"
                    ]
                },
                {
                    "_term": "systemic therapy",
                    "concepts": [
                        "('C1515119', 'Systemic Therapy', 'Therapeutic or Preventive Procedure', 'PT', 'NCI')",
                        "('C1515119', 'systemic therapy', 'Therapeutic or Preventive Procedure', 'PT', 'CHV')",
                        "('C1515119', 'systemic therapy', 'Therapeutic or Preventive Procedure', 'PT', 'NCI_NCI-GLOSS')",
                        "('C1515119', 'Systemic Therapy', 'Therapeutic or Preventive Procedure', 'SY', 'NCI_caDSR')",
                        "('C1515119', 'Systemic Therapy', 'Therapeutic or Preventive Procedure', 'DN', 'NCI_CTRP')"
                    ]
                }
            ]
        },
        {
            "_semantic_type": "Disease or Syndrome",
            "all_matches": [
                {
                    "_term": "progressive disease",
                    "concepts": [
                        "('C1335499', 'Progressive Disease', 'Disease or Syndrome', 'PT', 'NCI_GDC')",
                        "('C1335499', 'Progressive Disease', 'Disease or Syndrome', 'PT', 'NCI_ICDC')",
                        "('C3539781', 'Progressive Disease', 'Disease or Syndrome', 'SY', 'NCI')",
                        "('C1335499', 'Progressive disease', 'Disease or Syndrome', 'PT', 'NCI_CTDC')",
                        "('C1335499', 'Progressive Disease', 'Disease or Syndrome', 'PN', 'MTH')",
                        "('C1335499', 'Progressive Disease', 'Disease or Syndrome', 'SY', 'NCI_caDSR')",
                        "('C1335499', 'PROGRESSIVE DISEASE', 'Disease or Syndrome', 'PT', 'NCI_CDISC')",
                        "('C1335499', 'Progressive Disease', 'Disease or Syndrome', 'SY', 'NCI_CDISC')",
                        "('C1335499', 'Progressive disease', 'Disease or Syndrome', 'LA', 'LNC')",
                        "('C1335499', 'Progressive Disease', 'Disease or Syndrome', 'PT', 'NCI_PCDC')",
                        "('C1335499', 'Progressive Disease', 'Disease or Syndrome', 'PT', 'NCI')"
                    ]
                },
                {
                    "_term": "crs",
                    "concepts": [
                        "('C0010278', 'CRS', 'Disease or Syndrome', 'ETAL', 'OMIM')"
                    ]
                }
            ]
        }
    ],
    "indications": [
        {
            "_id": "149",
            "ct_disease": [
                "Melanoma",
                "Melanoma, Familial",
                "Acral Lentiginous Melanoma"
            ],
            "department": [
                "肿瘤科"
            ],
            "indication_type": [
                "肿瘤领域",
                "罕见疾病领域"
            ],
            "is_patent": "是",
            "name": "黑素瘤",
            "name_en": "melanoma (MEL)",
            "name_short": "MEL",
            "name_synonyms": [
                "黑色素瘤",
                "malignant melanoma",
                "melanoma"
            ],
            "parent_indication": [
                "148"
            ],
            "state": "正常"
        }
    ]
}